[Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2016 May 6

PMID 27146421

Citations 82

Authors

Richard Laforest

Suzanne E Lapi

Reiko Oyama

Ron Bose

Adel Tabchy

Bernadette V Marquez-Nostra

Jennifer Burkemper

Brian D Wright

Jennifer Frye

Sarah Frye

Barry A Siegel

Farrokh Dehdashti

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [Zr]trastuzumab in patients with HER2-positive breast cancer.

Procedures: Twelve women with HER2-positive breast cancer underwent [Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model.

Results: High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [Zr]trastuzumab were encountered.

Conclusion: [Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.

Citing Articles

Radiopharmaceuticals and their applications in medicine.

Zhang S, Wang X, Gao X, Chen X, Li L, Li G Signal Transduct Target Ther. 2025; 10(1):1.

PMID: 39747850 PMC: 11697352. DOI: 10.1038/s41392-024-02041-6.

Antibody-Based PET Imaging of Misfolded Superoxide Dismutase 1 in an Amyotrophic Lateral Sclerosis Mouse Model.

Rousseau J, Maier M, Ait-Mohand S, Dumulon-Perreault V, Sarrhini O, Tremblay S J Nucl Med. 2024; 66(1):130-135.

PMID: 39667814 PMC: 11705793. DOI: 10.2967/jnumed.124.268343.

[Cu]Cu-NOTA-Trastuzumab and [Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression.

Simo C, Shmuel S, Vanover A, Pereira P Mol Pharm. 2024; 21(12):6311-6322.

PMID: 39471823 PMC: 11611601. DOI: 10.1021/acs.molpharmaceut.4c00777.

Advances and challenges in immunoPET methodology.

Mohr P, van Sluis J, Lub-de Hooge M, Lammertsma A, Brouwers A, Tsoumpas C Front Nucl Med. 2024; 4:1360710.

PMID: 39355220 PMC: 11440922. DOI: 10.3389/fnume.2024.1360710.

Development of Mn Labeled Trastuzumab for Extended Time Point PET Imaging of HER2.

Omweri J, Saini S, Houson H, Tekin V, Pyles J, Parker C Mol Imaging Biol. 2024; 26(5):858-868.

PMID: 39192059 PMC: 11436409. DOI: 10.1007/s11307-024-01948-4.

References

Nahta R, Yu D, Hung M, Hortobagyi G, Esteva F . Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006; 3(5):269-80. DOI: 10.1038/ncponc0509. View

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

Beylergil V, Morris P, Smith-Jones P, Modi S, Solit D, Hudis C . Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nucl Med Commun. 2013; 34(12):1157-65. PMC: 3815146. DOI: 10.1097/MNM.0b013e328365d99b. View

Dijkers E, de Vries E, Kosterink J, Brouwers A, Lub-de Hooge M . Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy. Curr Pharm Des. 2008; 14(31):3348-62. DOI: 10.2174/138161208786549425. View

Price-Schiavi S, Jepson S, Li P, Arango M, Rudland P, Yee L . Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer. 2002; 99(6):783-91. DOI: 10.1002/ijc.10410. View

Dijkers E, Munnink T, Kosterink J, Brouwers A, Jager P, de Jong J . Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010; 87(5):586-92. DOI: 10.1038/clpt.2010.12. View

Wulfing P, Borchard J, Buerger H, Heidl S, Zanker K, Kiesel L . HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006; 12(6):1715-20. DOI: 10.1158/1078-0432.CCR-05-2087. View

Mortimer J, Bading J, Colcher D, Conti P, Frankel P, Carroll M . Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. J Nucl Med. 2013; 55(1):23-9. PMC: 4084518. DOI: 10.2967/jnumed.113.122630. View

Rosenthal S, Depowski P, Sheehan C, Ross J . Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol. 2002; 10(1):40-6. DOI: 10.1097/00129039-200203000-00007. View

10.

Burris 3rd H, Rugo H, Vukelja S, Vogel C, Borson R, Limentani S . Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2010; 29(4):398-405. DOI: 10.1200/JCO.2010.29.5865. View

11.

Barron J, Cziraky M, Weisman T, Hicks D . HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist. 2009; 14(8):760-8. DOI: 10.1634/theoncologist.2008-0288. View

12.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

13.

Gross M, Shazer R, Agus D . Targeting the HER-kinase axis in cancer. Semin Oncol. 2004; 31(1 Suppl 3):9-20. DOI: 10.1053/j.seminoncol.2004.01.005. View

14.

Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K . (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res. 2015; 5:8. PMC: 4385241. DOI: 10.1186/s13550-015-0082-6. View

15.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

16.

Berns K, Horlings H, Hennessy B, Madiredjo M, Hijmans E, Beelen K . A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007; 12(4):395-402. DOI: 10.1016/j.ccr.2007.08.030. View

17.

Gebhart G, Lamberts L, Wimana Z, Garcia C, Emonts P, Ameye L . Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2015; 27(4):619-24. DOI: 10.1093/annonc/mdv577. View

18.

Capala J, Bouchelouche K . Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Curr Opin Oncol. 2010; 22(6):559-66. PMC: 3401024. DOI: 10.1097/CCO.0b013e32833f8c3a. View

19.

Carlson R, Larsen J, McClure J, Fitzgerald C, Venook A, Benson 3rd A . International adaptations of NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2014; 12(5):643-8. DOI: 10.6004/jnccn.2014.0068. View

20.

Mack L, Kerkvliet N, Doig G, OMalley F . Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. Hum Pathol. 1997; 28(8):974-9. DOI: 10.1016/s0046-8177(97)90014-9. View